These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Resistance profile of rilpivirine]. Imaz A; García F; di Yacovo S; Llibre JM Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532 [TBL] [Abstract][Full Text] [Related]
4. Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons. Calvez V; Marcelin AG; Vingerhoets J; Hill A; Hadacek B; Moecklinghoff C Antivir Ther; 2016; 21(5):405-12. PubMed ID: 26761642 [TBL] [Abstract][Full Text] [Related]
5. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069 [TBL] [Abstract][Full Text] [Related]
6. Genotypic resistance testing in HIV-infected pregnant women in an urban setting. Shah SS; Crane M; Monaghan K; McGowan JP Int J STD AIDS; 2004 Jun; 15(6):384-7. PubMed ID: 15186583 [TBL] [Abstract][Full Text] [Related]
7. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993 [TBL] [Abstract][Full Text] [Related]
8. An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS. Skalweit MJ Int J STD AIDS; 2016 Dec; 27(14):1346-1349. PubMed ID: 27074792 [TBL] [Abstract][Full Text] [Related]
9. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. Paredes R; Cheng I; Kuritzkes DR; Tuomala RE AIDS; 2007 Oct; 21(15):2103-6. PubMed ID: 17885302 [TBL] [Abstract][Full Text] [Related]
10. Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey. Sayan M; Sultanoglu N; Sanlidag T AIDS Res Hum Retroviruses; 2023 Feb; 39(2):84-90. PubMed ID: 36301912 [TBL] [Abstract][Full Text] [Related]
11. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV. Giuliano M; Galluzzo CM; Germinario EA; Amici R; Bassani L; Dehò L; Vyankandondera J; Mmiro F; Okong P; Vella S J Acquir Immune Defic Syndr; 2006 May; 42(1):131-3. PubMed ID: 16763503 [No Abstract] [Full Text] [Related]
12. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451 [TBL] [Abstract][Full Text] [Related]
13. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. Poveda E; Garrido C; de Mendoza C; Corral A; Cobo J; González-Lahoz J; Soriano V J Antimicrob Chemother; 2007 Dec; 60(6):1409-10. PubMed ID: 17913723 [No Abstract] [Full Text] [Related]
15. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999. Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642 [TBL] [Abstract][Full Text] [Related]
17. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois. Kuritzkes DR HIV Clin Trials; 2001; 2(3):219-26. PubMed ID: 11590531 [No Abstract] [Full Text] [Related]
18. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. Morris L; Pillay C; Chezzi C; Lupondwana P; Ntsala M; Levin L; Venter F; Martinson N; Gray G; McIntyre J AIDS; 2003 Jul; 17(11):1698-700. PubMed ID: 12853755 [TBL] [Abstract][Full Text] [Related]
19. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China. Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969 [TBL] [Abstract][Full Text] [Related]
20. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia. Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]